Combining ICIs and angiogenesis inhibitors improved the prognosis in RCC and NSCLC patients with positive PD-L1 expression, and more clinical benefits of combining ICIs with T-DM1 in patients with HER2-positive advanced breast cancer were only observed in the PD-L1 positive subgroup [54,60,76]. The gene discussed is ERBB2; the disease is renal cell carcinoma.